Pathology & Veterinary Support for Preclinical Toxicology

该合同的目的是支持发展治疗项目（DTP）的药物开发工作，并为癌症治疗和诊断部门（DCTD）执行关键活动，以便允许潜在的候选药物进行临床试验。毒理学研究是在完整、健康的实验动物身上进行的，是临床前药物开发计划的最后一步。在确定药物的安全性和毒性以及毒性的可逆性时，对被评估药物产生的病变进行组织学检查是一个至关重要的终点。

The objective of this contract is to support the Developmental Therapeutics Program's (DTP) drug development effort and also perform critical activities for the Division of Cancer Treatment and Diagnosis (DCTD) in order to allow potential drug candidates proceed to clinical trials. Toxicology studies are conducted in intact, healthy, experimental animals as the final step in the preclinical drug development scheme. Histologic examination of lesions produced by the drug under evaluation is a crucial endpoint in the determination of a drug's safety and toxicity and in the reversibility of that toxicity. This contract supports the NCI in a variety of functions including, independent pathology assessment of toxicology studies (assures quality and consistency amongst the contract laboratories); necropsy and histopathology support for studies as needed; repository storage of pathology materials and DTP documents; determination of tissue binding specificity of therapeutic antibodies; and performance of specialized histologic procedures such as immunohistochemistry.